{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:27:28Z","timestamp":1787135248677,"version":"build-2736575974"},"reference-count":25,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Issues Mol. Biol.","CIMB"],"abstract":"<jats:p>The present study investigated the anticancer effects of irinotecan (IR) combined with the acid ceramidase inhibitor Ceranib-2 in HT-29 human colorectal cancer cells. Cell viability was assessed using the MTT assay, apoptosis was evaluated by Annexin V flow cytometry, and morphological alterations were examined by fluorescence microscopy. Both irinotecan and Ceranib-2 significantly reduced cell viability in a dose-dependent manner. Notably, the combination treatment produced greater growth inhibition than either agent alone (p &lt; 0.01). Morphological analysis revealed pronounced apoptotic features, including nuclear condensation, membrane blebbing, and cytoskeletal disruption, particularly in the combination-treated cells. Annexin V analysis further demonstrated that combined treatment markedly increased apoptotic cell populations compared with single-agent treatments (p &lt; 0.01). These findings suggest that Ceranib-2 enhances the anticancer activity of irinotecan and that this combination may represent a promising therapeutic strategy for colorectal cancer.<\/jats:p>","DOI":"10.3390\/cimb48080841","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:30:53Z","timestamp":1787131853000},"page":"841","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Effects of Ceranib-2 and Irinotecan Combination on Colon Cancer"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-1107","authenticated-orcid":false,"given":"O\u011fuzhan","family":"Selvi","sequence":"first","affiliation":[{"name":"Medical Oncology Clinic, Faculty of Medicine, Bezmialem Vakif University, \u0130stanbul 34093, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-5993","authenticated-orcid":false,"given":"Canan","family":"Vejselova Sezer","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Arts and Sciences, K\u00fctahya Dumlup\u0131nar University, K\u00fctahya 43100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-2988","authenticated-orcid":false,"given":"H\u00fcseyin","family":"\u0130zg\u00f6rd\u00fc","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Sciences, Eskisehir Osmangazi University, Eskisehir 26040, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Mehtap","family":"Kutlu","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Science, Eskisehir Technical University, Eskisehir 26470, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-001-0416-0","article-title":"Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines","volume":"49","author":"Pavillard","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3906\/biy-1405-36","article-title":"Cytotoxic and apoptotic effects of ceranib-2 offering potential for a new antineoplastic agent in the treatment of cancer cells","volume":"38","author":"Vejselova","year":"2014","journal-title":"Turk. J. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI97949","article-title":"Role of sphingolipids in senescence: Implication in aging and age-related diseases","volume":"128","author":"Trayssac","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Janneh, A.H., and Ogretmen, B. (2022). Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment. Cancers, 14.","DOI":"10.3390\/cancers14092183"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gupta, P., Taiyab, A., Hussain, A., Alajmi, M.F., Islam, A., and Hassan, I. (2021). Targeting the Sphingosine Kinase\/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy. Cancers, 13.","DOI":"10.3390\/cancers13081898"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Li, R.-Z., Wang, X.-R., Wang, J., Xie, C., Wang, X.-X., Pan, H.-D., Meng, W.-Y., Liang, T.-L., Li, J.-X., and Yan, P.-Y. (2022). The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.941643"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-394274-6.00002-9","article-title":"Chapter Two\u2014Diverse functions of ceramide in cancer cell death and proliferation","volume":"117","author":"Saddoughi","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/CAD.0000000000000566","article-title":"Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK\/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ER\u03b1","volume":"29","author":"Vethakanraj","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"ref_11","first-page":"4187","article-title":"Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato","year":"1991","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4781(95)00029-G","article-title":"Eukaryotic DNA topoisomerases I","volume":"1262","author":"Gupta","year":"1995","journal-title":"Biochim. Biophys. Acta Gene Struct. Expr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0167-4781(98)00129-8","article-title":"Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme","volume":"1400","author":"Pommier","year":"1998","journal-title":"Biochim. Biophys. Acta (BBA) Gene Struct. Expr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.46309\/biodicon.2025.1604413","article-title":"Modulation of sphingolipid metabolism: Investigation of the apoptotic and cytotoxic effects of the ceramidase Inhibitor D-e-MAPP in HT29 colon cancer cells","volume":"18","author":"Selvi","year":"2025","journal-title":"Biol. Divers. Conserv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s10616-016-9997-7","article-title":"Examining impacts of ceranib-2 on the proliferation, morphology and ultrastructure of human breast cancer cells","volume":"68","author":"Vejselova","year":"2016","journal-title":"Cytotechnology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-2187-6-7","article-title":"Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells","volume":"6","author":"Nautiyal","year":"2011","journal-title":"J. Mol. Signal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.7314\/APJCP.2015.16.5.1993","article-title":"Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: A Systemic Analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1200\/JCO.2014.56.3387","article-title":"Irinotecan Pharmacogenetics: A Finished Puzzle?","volume":"32","author":"Phelps","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/tox.22268","article-title":"Inhibition of NF-\u03baB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38","volume":"32","author":"Chen","year":"2016","journal-title":"Environ. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3892\/ol.2017.6407","article-title":"Treatment mechanism of matrine in combination with irinotecan for colon cancer","volume":"14","author":"Duan","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Espinoza, K.S., and Snider, A.J. (2024). Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer. Cancers, 16.","DOI":"10.3390\/cancers16040789"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4149\/BLL_2017_076","article-title":"Effects of ceranib-2 on cell survival and TNF-alpha in colon cancer cell line","volume":"118","author":"Baspinar","year":"2017","journal-title":"Bratisl. Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Afrin, F., Mateen, S., Oman, J., Lai, J.C.K., Barrott, J.J., and Pashikanti, S. (2023). Natural Products and Small Molecules Targeting Cellular Ceramide Metabolism to Enhance Apoptosis in Cancer Cells. Cancers, 15.","DOI":"10.20944\/preprints202308.0497.v1"},{"key":"ref_25","first-page":"1487","article-title":"Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition","volume":"19","author":"Banias","year":"2020","journal-title":"Oncol. Lett."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/8\/841\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:57:31Z","timestamp":1787133451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/8\/841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cimb48080841"],"URL":"https:\/\/doi.org\/10.3390\/cimb48080841","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}